{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:26:42Z","timestamp":1790040402403,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["348041003"],"award-info":[{"award-number":["348041003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["636340001"],"award-info":[{"award-number":["636340001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.schres.2024.09.030","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T07:56:25Z","timestamp":1729410985000},"page":"299-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients"],"prefix":"10.1016","volume":"274","author":[{"given":"Franciska","family":"de Beer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Wijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Wouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiral","family":"Gangadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Veling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"van Beveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieuwe","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J.H.","family":"Begemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E.C.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.09.030_bb0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archpsyc.1992.01820080023004","article-title":"The comprehensive assessment of symptoms and history (CASH) an instrument for assessing diagnosis and psychopathology","volume":"49","author":"Andreassen","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.030_bb0010","first-page":"45","article-title":"Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials","volume":"43","author":"Ardizzone","year":"2010","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2024.09.030_bb0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3822-5","article-title":"To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction\/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial","volume":"21","author":"Begemann","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.schres.2024.09.030_bb0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.2005.00540.x","article-title":"The role of dopamine in reward and pleasure behaviour \u2013 review of data from preclinical research","volume":"111","author":"Bressan","year":"2005","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.09.030_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1257\/jep.15.4.29","article-title":"Semiparametric censored regression models","volume":"15","author":"Chay","year":"2001","journal-title":"J. Econ. Perspect."},{"key":"10.1016\/j.schres.2024.09.030_bb0030","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/0269881119872193","article-title":"An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: eight-week outcomes","volume":"33","author":"Cheng","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.09.030_bb0035","doi-asserted-by":"crossref","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2024.09.030_bb0040","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eurpsy.2014.01.007","article-title":"Impact of primary negative symptoms on functional outcomes in schizophrenia","volume":"29","author":"Fervaha","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.030_bb0045","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","article-title":"Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders","volume":"24","author":"Foussias","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.09.030_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.09.030_bb0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","article-title":"The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity","volume":"87","author":"Gerlach","year":"1993","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.09.030_bb0060","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","article-title":"Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications","volume":"157","author":"Hartling","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.schres.2024.09.030_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.schres.2009.05.030","article-title":"Effectiveness of second-generation antipsychotics with acute-phase schizophrenia","volume":"113","author":"Hatta","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.09.030_bb0070","series-title":"Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia","author":"Horacek","year":"2006"},{"key":"10.1016\/j.schres.2024.09.030_bb0075","series-title":"Amisulpride, Aripiprazole, and Olanzapine in Patients with Schizophrenia-Spectrum Disorders (BeSt InTro): A Pragmatic, Rater-Blind, Semi-Randomised Trial","author":"Johnsen","year":"2020"},{"issue":"5","key":"10.1016\/j.schres.2024.09.030_bb4000","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1192\/bjp.166.5.654","article-title":"A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF)","volume":"166","author":"Jones","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.030_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1751-7893.2010.00163.x","article-title":"Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study","volume":"4","author":"Josiassen","year":"2010","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.030_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2024.09.030_bb0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.09.030_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006569.pub4","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","author":"Khanna","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2024.09.030_bb0100","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","article-title":"Unique effects of clozapine: a pharmacological perspective","author":"Khokhar","year":"2018"},{"key":"10.1016\/j.schres.2024.09.030_bb0105","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.09.030_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","article-title":"Secondary negative symptom - a review of mechanisms, assessment and treatment","volume":"186","author":"Kirschner","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.09.030_bb0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/appi.ajp.2012.12010109","article-title":"The clinical assessment interview for negative symptoms (CAINS): final development and validation","volume":"170","author":"Kring","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.030_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/acps.12030","article-title":"Psychopathological long-term outcome of schizophrenia \u2014 a review","author":"Lang","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.09.030_bb0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.schres.2024.09.030_bb0130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.030_bb0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.030_bb0140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine Partial Agonists","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2024.09.030_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.766692","article-title":"Primary and secondary negative symptoms in schizophrenia","author":"Mosolov","year":"2022","journal-title":"Front. Psych."},{"key":"10.1016\/j.schres.2024.09.030_bb0150","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.09.030_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2296-10-32","article-title":"Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care","volume":"10","author":"Oud","year":"2009","journal-title":"BMC Fam. Pract."},{"key":"10.1016\/j.schres.2024.09.030_bb0160","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020"},{"key":"10.1016\/j.schres.2024.09.030_bb0165","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-017-0789-y","article-title":"Treatment for negative symptoms in schizophrenia: a comprehensive review","author":"Veerman","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.schres.2024.09.030_bb0170","series-title":"ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R","author":"Wright","year":"2016"},{"key":"10.1016\/j.schres.2024.09.030_bb0175","doi-asserted-by":"crossref","first-page":"e1460","DOI":"10.4088\/JCP.15m10047","article-title":"Effectiveness of antipsychotic drugs for 24-month maintenance treatment in first-episode schizophrenia","volume":"77","author":"Zhang","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.030_bb0180","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","article-title":"Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses","volume":"4","author":"Zhu","year":"2017","journal-title":"Lancet Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424004390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424004390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:39:49Z","timestamp":1762317589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424004390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"alternative-id":["S0920996424004390"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.09.030","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}